10x Genomics (TXG) Scheduled to Post Earnings on Tuesday

10x Genomics (NASDAQ:TXG) will be posting its quarterly earnings results after the market closes on Tuesday, April 30th. Analysts expect 10x Genomics to post earnings of ($0.46) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings results on Thursday, February 15th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.05). 10x Genomics had a negative net margin of 41.17% and a negative return on equity of 28.82%. The firm had revenue of $183.98 million for the quarter, compared to analysts’ expectations of $182.73 million. During the same period in the prior year, the company earned ($0.15) EPS. The firm’s quarterly revenue was up 17.8% on a year-over-year basis. On average, analysts expect 10x Genomics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

10x Genomics Price Performance

Shares of NASDAQ TXG opened at $27.59 on Friday. 10x Genomics has a one year low of $26.30 and a one year high of $63.57. The business’s fifty day moving average price is $37.70 and its 200-day moving average price is $42.53. The stock has a market capitalization of $3.29 billion, a PE ratio of -12.71 and a beta of 1.90.

Wall Street Analyst Weigh In

TXG has been the topic of a number of recent research reports. Barclays dropped their price objective on 10x Genomics from $55.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, April 10th. Deutsche Bank Aktiengesellschaft dropped their price objective on 10x Genomics from $60.00 to $55.00 and set a “buy” rating on the stock in a report on Thursday, April 18th. Finally, Stifel Nicolaus dropped their price objective on 10x Genomics from $68.00 to $63.00 and set a “buy” rating on the stock in a report on Friday, February 16th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.22.

Insider Buying and Selling

In related news, CEO Serge Saxonov sold 4,660 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $44.00, for a total transaction of $205,040.00. Following the transaction, the chief executive officer now directly owns 842,900 shares in the company, valued at approximately $37,087,600. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, CFO Justin J. Mcanear sold 1,865 shares of 10x Genomics stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total value of $86,424.10. Following the sale, the chief financial officer now directly owns 95,240 shares in the company, valued at approximately $4,413,421.60. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Serge Saxonov sold 4,660 shares of 10x Genomics stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $44.00, for a total value of $205,040.00. Following the completion of the sale, the chief executive officer now owns 842,900 shares in the company, valued at $37,087,600. The disclosure for this sale can be found here. Insiders have sold a total of 12,959 shares of company stock worth $592,806 in the last ninety days. 10.65% of the stock is owned by insiders.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.